Fractalkine levels are elevated early after PCI-treated ST-elevation myocardial infarction; no influence of autologous bone marrow derived stem cell injection

Cytokine

Volumn 69, Issue 1, 2014, Pages 131-135

  Njerve, Ida Unhammer ^a,b,d   Solheim, Svein ^a,b   Lunde, Ketil ^c   Hoffmann, Pavel ^a   Arnesen, Harald ^a,b,d   Seljeflot, Ingebjørg ^a,b,d  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

Acute myocardial infarction; Autologous mononuclear bone marrow cells (mBMC); CX3CR1; Fractalkine

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; CREATINE KINASE MB; FRACTALKINE; RNA; TROPONIN T; CHEMOKINE RECEPTOR; CX3CL1 PROTEIN, HUMAN; CX3CR1 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ATHEROSCLEROSIS; BIOSYNTHESIS; BLOOD; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; HEART; HEART INFARCTION; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; STEM CELL; STEM CELL TRANSPLANTATION;

ANGINA;

ADULT; AGED; ANGINA PECTORIS; ATHEROSCLEROSIS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CHEMOKINE CX3CL1; CORONARY ANGIOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RECEPTORS, CHEMOKINE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84904171249     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.05.022     Document Type: Article

References (24)

1. Umehara H., Bloom E.T., Okazaki T., Nagano Y., Yoshie O., Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004, 24:34-40.
2. Bazan J.F., Bacon K.B., Hardiman G., et al. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644.
3. Landsman L., Bar-On L., Zernecke A., et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 2009, 113:963-972.
4. Husberg C., Nygard S., Finsen A.V., et al. Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure. J Mol Cell Cardiol 2008, 45:261-269.
5. Richter B., Koller L., Hohensinner P.J., et al. Fractalkine is an independent predictor of mortality in patients with advanced heart failure. Thromb Haemost 2012, 108:1220-1227.
6. Xuan W., Liao Y., Chen B., et al. Detrimental effect of fractalkine on myocardial ischaemia and heart failure. Cardiovasc Res 2011, 92:385-393.
7. White G.E., Tan T.C., John A.E., Whatling C., McPheat W.L., Greaves D.R. Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res 2010, 85:825-835.
8. Clifford D.M., Fisher S.A., Brunskill S.J., et al. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012, 2:CD006536.
9. Korf-Klingebiel M., Kempf T., Sauer T., et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur Heart J 2008, 29:2851-2858.
10. Solheim S., Grogaard H.K., Hoffmann P., Arnesen H., Seljeflot I. Inflammatory responses after percutaneous coronary intervention in patients with acute myocardial infarction or stable angina pectoris. Scand J Clin Lab Invest 2008, 68:555-562.
11. Lunde K., Solheim S., Aakhus S., et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. New Engl J Med 2006, 355:1199-1209.
12. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
13. Lunde K., Solheim S., Forfang K., et al. Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months' follow-up. J Am Coll Cardiol 2008, 51:674-676.
14. Damas J.K., Boullier A., Waehre T., et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005, 25:2567-2572.
15. Yao K., Lu H., Huang R., et al. Changes of dendritic cells and fractalkine in type 2 diabetic patients with unstable angina pectoris: a preliminary report. Cardiovasc Diabetol 2011, 10:50.
16. Li J., Guo Y., Luan X., et al. Independent roles of monocyte chemoattractant protein-1, regulated on activation, normal T-cell expressed and secreted and fractalkine in the vulnerability of coronary atherosclerotic plaques. Circ J 2012, 76:2167-2173.
17. Ikejima H., Imanishi T., Tsujioka H., et al. Upregulation of fractalkine and its receptor, CX3CR1, is associated with coronary plaque rupture in patients with unstable angina pectoris. Circ J 2010, 74:337-345.
18. Wong B.W., Wong D., McManus B.M. Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol 2002, 11:332-338.
19. Garton K.J., Gough P.J., Blobel C.P., et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 2001, 276:37993-38001.
20. Satoh M., Ishikawa Y., Itoh T., Minami Y., Takahashi Y., Nakamura M. The expression of TNF-alpha converting enzyme at the site of ruptured plaques in patients with acute myocardial infarction. Eur J Clin Invest 2008, 38:97-105.
21. Alves G.D., Pazzine M., Gomes de Macedo Braga L.M., et al. Molecular mapping of the regenerative niche in a murine model of myocardial infarction. Int J Mol Med 2012, 29:479-484.
22. Henning R.J., Shariff M., Eadula U., et al. Human cord blood mononuclear cells decrease cytokines and inflammatory cells in acute myocardial infarction. Stem Cells Dev 2008, 17:1207-1219.
23. Njerve I.U., Pettersen A.A., Opstad T.B., Arnesen H., Seljeflot I. Fractalkine and its receptor (CX3CR1) in patients with stable coronary artery disease and diabetes mellitus. Metab Synd Relat Disord 2012, 10:400-406.
24. Solheim S., Seljeflot I., Lunde K., et al. Inflammatory responses after intracoronary injection of autologous mononuclear bone marrow cells in patients with acute myocardial infarction. Am Heart J 2008, 155. 55.e1-55.e9.